~0 spots leftby Apr 2026

Islet Transplantation for Type 1 Diabetes

Recruiting in Palo Alto (17 mi)
Overseen byAndrew M Posselt, MD, PhD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: University of California, San Francisco
No Placebo Group

Trial Summary

What is the purpose of this trial?

The goal of this trial is to gain initial clinical experience regarding the safety and efficacy of treating type I diabetes in people who have received a kidney transplant by transplanting islets into a new transplant site in the stomach (gastrointestinal submucosa). A total of 6 patients will be enrolled in the study and followed for a period of up to 3 years after the last islet transplant.

Eligibility Criteria

This trial is for adults aged 18-70 with Type 1 Diabetes who have had a kidney transplant and are on specific immunosuppression drugs. They must have stable renal function, a history of severe hypoglycemia despite intensive diabetes management, and no production of c-peptide. Exclusions include active infections like hepatitis or HIV, recent use of other anti-diabetic drugs or investigational agents, certain cardiovascular conditions, untreated hyperlipidemia, pregnancy or unwillingness to use contraception.

Inclusion Criteria

My c-peptide levels are very low after a special drink test.
I was diagnosed with Type 1 Diabetes before 40 and have been on insulin for over 5 years.
I had a kidney transplant over 3 months ago and am on specific immune-suppressing drugs.
See 5 more

Exclusion Criteria

My blood pressure is still high despite taking medication.
I have an active stomach ulcer, symptomatic gallstones, or high blood pressure in the liver.
I use more than 1.0 IU/kg/day or less than 15 units/day of insulin.
See 23 more

Treatment Details

Interventions

  • Islet cells (Cell Therapy)
  • Islet transplantation into the gastrointestinal submucosa (Cell Therapy)
Trial OverviewThe study tests the safety and effectiveness of transplanting islet cells into the stomach's lining in people with Type 1 Diabetes who've had a kidney transplant. Six patients will be enrolled to receive this treatment and monitored for up to three years post-transplant.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Islet TransplantExperimental Treatment2 Interventions
Islet transplantation into the gastrointestinal submucosa

Find a Clinic Near You

Research Locations NearbySelect from list below to view details:
University of California, San FranciscoSan Francisco, CA
Loading ...

Who Is Running the Clinical Trial?

University of California, San FranciscoLead Sponsor
Andrew PosseltLead Sponsor

References